this could have been due to ribavirin use in more severe patients.
In our previous study we showed that Turkish pediatric patients had a milder course of CCHF, 1 which might be due to a lower cytokine response in pediatric cases. Lower cytokine levels in pediatric patients in could be a good prognostic factor for a favorable outcome. 2 One randomized controlled trial evaluating the efficacy of ribavirin performed in Turkey, compared 64 patients who received ribavirin and 72 who did not showed no significant difference in mortality, proportion of patients requiring platelet transfusion, length of hospital stay, recovery time, or laboratory parameters. 3 However, that study included late cases and ribavirin might not be beneficial in late stages of the disease. Side effects of ribavirin are the major obstacle, such as bradycardia, genotoxicity, and mutagenicity. [4] [5] [6] [7] As the use of ribavirin in CCHF is still controversial 8,9 more data are warranted to reach a definitive conclusion.
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